Analysis of Reentry Test for the Donors Showing Reactivity or Grey Zone in a HBV Surface Antigen Assay by a Chemiluminescent Immunoassay.
10.17945/kjbt.2018.29.3.301
- Author:
Sunmi SHIN
1
;
Jungwon KANG
;
Kyeong Rak LEE
;
Geon Sik SHIN
;
Jae won KANG
;
Young Ik SEO
;
Hyukki MIN
Author Information
1. Blood Transfusion Research Institute, Korean Red Cross, Wonju, Korea. kangjaewon@redcross.or.kr
- Publication Type:Original Article
- Keywords:
HBsAg;
S/Co;
Reentry
- MeSH:
Antigens, Surface*;
Blood Safety;
Hand;
Hepatitis B Surface Antigens;
Humans;
Immunoassay*;
Information Management;
Mass Screening;
Red Cross;
Tissue Donors*
- From:Korean Journal of Blood Transfusion
2018;29(3):301-309
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: If donors who were deferred due to the reactivity or grey zone in HBV surface antigen (HBsAg) assay want to donate blood again, they need to pass reentry tests. On the other hand, approximately half of the donors who are subject to the reentry tests cannot be reentered. This study examined the association between the sample to cutoff (S/Co) value of the HBsAg assay and the final results of the reentry test. METHODS: This study analyzed the S/Co values of the HBsAg assay and the final results of the reentry tests for the 3,947 donors from January 2008 to December 2017 using the database of Blood Information Management System of the Korean Red Cross. RESULTS: 1,767 donors (44.8%) were not reentered among 3,947 deferred donors. Among 1,585 donors showing ≥10 of the S/Co value in the HBsAg screening test, 1,542 donors (97.3%) were not reentered. The additional reentry tests were performed on 120 donors who were not reentered in the first reentry test; 98 donors (81.7%) were still not reentered. Overall, 4.6% of the donors showing a grey zone in the HBsAg assay were not reentered. CONCLUSION: The reentry test needs to be restricted for the deferred donors showing a more than 10 S/Co value. The application of the grey zone of current HBsAg assay will need to be continued to enhance the HBV-related blood safety.
